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Antisense Therapy for a Common Corneal Dystrophy
Ameliorates TCF4 Repeat Expansion-Mediated Toxicity
Christina Zarouchlioti,1,8 Beatriz Sanchez-Pintado,1,8 Nathaniel J. Hafford Tear,1,8 Pontus Klein,2
Petra Liskova,3,4 Kalyan Dulla,2 Ma’ayan Semo,1 Anthony A. Vugler,1 Kirithika Muthusamy,1,5
Lubica Dudakova,3 Hannah J. Levis,6 Pavlina Skalicka,3,4 Pirro Hysi,7 Michael E. Cheetham,1
Stephen J. Tuft,1,5 Peter Adamson,2,9 Alison J. Hardcastle,1,9 and Alice E. Davidson1,9,*
Fuchs endothelial corneal dystrophy (FECD) is a common disease for which corneal transplantation is the only treatment option in
advanced stages, and alternative treatment strategies are urgently required. Expansion (R50 copies) of a non-coding trinucleotide repeat
in TCF4 confers >76-fold risk for FECD in our large cohort of affected individuals. An FECD subject-derived corneal endothelial cell
(CEC) model was developed to probe disease mechanism and investigate therapeutic approaches. The CEC model demonstrated that
the repeat expansion leads to nuclear RNA foci, with the sequestration of splicing factor proteins (MBNL1 and MBNL2) to the foci
and altered mRNA processing. Antisense oligonucleotide (ASO) treatment led to a significant reduction in the incidence of nuclear
foci, MBNL1 recruitment to the foci, and downstream aberrant splicing events, suggesting functional rescue. This proof-of-concept
study highlights the potential of a targeted ASO therapy to treat the accessible and tractable corneal tissue affected by this repeat expan-
sion-mediated disease.Introduction
Fuchs endothelial corneal dystrophy (FECD [MIM: 613267])
is a common, degenerative, age-related condition that usu-
ally presents during the fifth to sixth decade. The disease
primarily affects the posterior cornea with the hallmark
being the formation of focal excrescences of Descemet
membrane (DM) termed ‘‘guttae.’’ Isolated guttae are com-
mon in the elderly and a case definition for FECD usually
requires that the guttae are confluent. When assessed with
specular microscopy, the prevalence of guttae is higher in
white (11.2% >55 years) than East Asian (5.5% >50 years)
populations and higher in females (5.5%–11%) than males
(1.5%–7%).1,2 An estimate of the prevalence of confluent
guttae in individuals of white or black ethnicity >50 years
with assessment by slit-lamp biomicroscopy reported a
figure of 4.5%.3 Confluent guttae can be associated with a
loss of corneal endothelial cell density to a critical stage
when the remaining endothelium is unable to maintain
appropriate stromal dehydration leading to fluid accumula-
tion, painful epithelial bullae, and progressive corneal
clouding reducing visual acuity.4–6 Early-stage disease is
typically managed with topical hypertonic saline to reduce
symptoms, such as corneal swelling, but surgical interven-
tion is currently the only treatment option available to
individuals with advanced disease to restore bilateral vision
and prevent blindness.6 Full or partial keratoplasty are
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is a global shortage.7 These issues, coupled with the global
aging population, highlight the need for alternative and
effective treatment strategies.
In 2010, a landmark FECD genome-wide association
study (GWAS) identified a strong association with com-
mon non-coding variants located within the transcription
factor encoding gene TCF4 (MIM: 602272). The risk allele
of the most highly associated SNP (rs613872) conferred a
remarkably high odds ratio (OR) of 5.5 for individuals
carrying one copy or an OR of 30 for individuals with
two copies.8 Subsequently, the SNP rs613872 was found
to be in linkage disequilibrium with CTG18.1, a CTG
repeat expansion situated within an intronic region of
TCF4, connecting the initial GWAS signal with a putative
functional variant.9 This association has now been repli-
cated in a range of ethnically distinct cohorts, supporting
the hypothesis that expanded copies of the CTG18.1
repeat are associated with FECD.10–14
Transcripts containing expanded copies of the CUG
repeat accumulate as discrete nuclear RNA foci within tis-
sue derived from individuals affected with FECD;15 similar
to other repeat expansion-associated disorders, such as
myotonic dystrophy type 1 (DM1 [MIM: 160900]), which
is caused by an identical CTG repeat expansion located
within the 30 untranslated region (UTR) of DMPK (MIM:
605377).16,17 DM1 pathogenesis has largely been attrib-
uted to these RNA aggregates sequestering RNA-splicings, Zernikedreef 9, 2333 CK Leiden, the Netherlands; 3Research Unit for Rare
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Table 1. Summary of CTG18.1 Genotyping Data in the FECD Cohort
N NE/NE E/NE E/E R1 E
Total FECD cohort (mean age ¼ 69) 450 23.6% (106/450) 72.4% (326/450) 4.0% (18/450) 76.4% (344/450)
Females (mean age ¼ 70) 265 27.2% (72/265) 69.1% (183/265) 3.8% (10/265) 72.8% (193/265)
Males (mean age ¼ 68) 185 18.4% (34/185) 77.3% (143/185) 4.3% (8/185) 81.6% (151/185)
Subjects recruited at MEH 318 25.5% (81/318) 70.1% (223/318) 4.4% (14/318) 74.5% (237/318)
White (82.4%) 260 22.7% (59/260) 71.9% (187/260) 5.4% (14/260) 77.3% (201/260)
Other (17.6%) 58 37.9% (22/58) 62.1% (36/58) 0.0% (0/58) 62.1% (36/58)
Subjects recruited at GUH (white) 132 18.9% (25/132) 78.0% (103/132) 3.0% (4/132) 81.1% (107/132)
AMD cohort (mean age ¼ 78) 550 95.8% (527/550) 4.2% (23/550) 0.0% (0/550) 4.2% (23/550)
Females (mean age ¼ 78) 356 96.1% (342/356) 3.9% (14/356) 0.0% (0/356) 3.9% (14/356)
Males (mean age ¼ 78) 194 95.4% (185/194) 4.6% (9/194) 0.0% (0/194) 4.6% (9/194)
Expanded alleles are defined asR50 CTG repeats. Abbreviations are as follows: NE, non-expanded CTG18.1 allele; E, expanded CTG18.1 allele; MEH, Moorfields
Eye Hospital; GUH, General University Hospital in Prague.
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functional deficiency of these proteins and subsequent
global disruption of splicing.21,22
Studies using DM1 cell and animal models have shown
that targeting the CTG expansion within DMPK using an
antisense oligonucleotide (ASO) approach leads to a reduc-
tion in RNA foci and downstream markers of toxicity.23,24
To determine whether similar strategies could be effective
for CTG18.1-associated FECD and to translate FECD
therapies into the clinic, appropriate FECD disease models
are essential. Given the lack of animal models for FECD,
coupled with the general poor association of animal model
phenotypes with human complex disease, corneal endo-
thelial cell (CEC) cultures derived from affected individuals
offer an ideal opportunity to probe disease mechanism and
investigate therapeutic approaches.
Here we demonstrate that the TCF4 CTG18.1 expansion
confers a highly significant disease risk in our large cohort
of individuals affected by FECD. Our data define trinucleo-
tide repeat size as a fundamental driver of RNA foci inci-
dence in CECs. We identify downstream markers of RNA
toxicity and assess the effectiveness of a targeted ASO treat-
ment strategy for CTG18.1 expansion-associated FECD.Material and Methods
Subject Recruitment and Phenotyping
The study followed the tenets of the Declaration of Helsinki and
was approved by Moorfields Eye Hospital (MEH) ethics committee
(REC reference 09/H0724/25) and the Ethics committee of the
GUH, Czech Republic. Written informed consent was received
from all participants included in this study. A total of 450 individ-
uals (185 males and 265 females; mean cohort age, 69 years) were
recruited to the study. Participants either had clinical signs of
FECD (numerous corneal guttae on slit-lamp biomicroscopy) or
had corneal transplantation surgery (either penetrating or endo-
thelial keratoplasty) for FECD. The cohort was stratified based on
gender and ethnicity (Table 1). For control purposes, DNA samples2 The American Journal of Human Genetics 102, 1–12, April 5, 2018collected from 550 white European individuals with AMD were
used in the study (194 males and 356 females; mean cohort age,
78 years) (Table 1). All risk calculations presented were performed
using the white European samples only (392 FECD samples and
550 AMD samples).
TCF4 Expansion Genotyping
Genomic DNA was extracted from whole blood using conven-
tional methodologies. A short tandem repeat (STR) assay was
performed to genotype the CTG18.1 allele, in accordance
with methods previously published by Wieben et al.9 In brief,
genomic DNA was amplified using a 50FAM conjugated primer
(50-CAGATGAGTTTGGTGTAAGAT-30) and an unlabeled reverse
primer (50-ACAAGCAGAAAGGGGGCTGCAA-30). Post PCR prod-
uct separation was performed on the ABI 3730 Electrophoresis
96 capillary DNA analyzer (Applied Biosystems). Data analysis
was performed using GeneMarker software (SoftGenetics).
Collection of Endothelial Tissue Samples
Tissue derived from individuals affected by FECD was removed
during endothelial keratoplasty surgery performed at MEH. As
part of the procedure, 8 mm diameter discs of DM with attached
endothelial cells were removed from the posterior surface of
the central cornea. Control tissue, considered suitable for
transplantation, was obtained from corneo-scleral rims stored
in OptiSol-GS (Bausch & Lomb). All prepared tissue was stored
in Lebovitz L15 Media (Life Technologies) supplemented
with 1% antibiotic/antimycotic prior to being processed in the
laboratory.
Primary CEC Culture
CECs retrieved from control tissue and from subjects diagnosed
with FECD were cultured in accordance with a dual media
approach described by Peh et al.25 In brief, donated tissue
comprising DM with attached endothelial cells was incubated in
0.2% collagenase type I powder in M5 media (Life Technologies)
for 3 hr at 37C to dislodge CECs from the DM. CECs were
centrifuged and re-suspended again in M5 media to allow for
cell adherence and stabilization. Media M5 contained Human
Endothelial-SFM (Life Technologies) supplemented with 5% FBS,
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Y-27632 (AdooQ BioScience). Cells were seeded in cell culture
ware pre-coated with FNC coating mixture (United States
Biological). After 24 hr, to promote proliferation, culture
media was replaced with M4 media containing Ham’s F-12
Nutrient Mix GlutaMAX Supplement (Life Technologies)/Medium
199 GlutaMAX Supplement (Life Technologies), 20 mg/mL
ascorbic acid, 1% insulin-transferrin-selenium (Life Technologies),
5% FBS, 1% antibiotic/antimycotic, 10 ng/mL bFGF (R&D
Systems), and 0.1% selective ROCK inhibitor Y-27632 (AdooQ
BioScience). Throughout culture, cells were kept in an incubator
at 37C, 5% CO2 and medium was refreshed every 48 hr until
the cells showed appropriate confluence for experimentation or
passage. Cells were passaged a maximum of two times prior to
any experiment being performed.
Generation of Fibroblast Cell Lines from Dermal Skin
Biopsies
Primary fibroblast lines were generated as described by Carter
et al.26 Briefly, 5 mm skin biopsies were obtained under aseptic
conditions and were shortly stored in DMEM/F-12, GlutaMAX
(Life Technologies) supplemented with 10% FBS and 1% peni-
cillin/streptomycin at 4C until being processed. After the
epidermal layer was removed, the biopsy samples were dissected
into small pieces which were then immobilized under a glass
coverslip for 24 hr (37C, 5% CO2). Fresh medium was added
the following day and renewed every 2–3 days. At 70% conflu-
ence, the cultures were passed through a cell strainer to remove
pieces of tissue and finally seeded in T25 flasks.
Immunocytochemistry (ICC)
CECs grown on glass coverslips were fixed with 4% paraformal-
dehyde (PFA) in PBS for 10 min. After washing with PBS, cells
were permeabilized with 0.1% Triton X-100 for 10 min and
non-specific binding sites were blocked in PBS with 3% BSA
and 10% donkey serum for 1 hr. The CECs were incubated with
primary antibodies, diluted to the appropriate concentration
(Table S1), in blocking solution overnight at 4C. For MBNL127
and MBNL2 antibodies, 0.5% Triton X-100 was incorporated
in the blocking solution instead, omitting the previous permea-
bilization step, and proceeding normally after. After washing
with PBS, CECs were incubated in donkey fluorophore-bound
secondary antibodies (Alexa Fluor 488, anti-mouse or anti-rabbit;
Invitrogen) diluted 1:1,000 in 3% BSA PBS for 1 hr at room
temperature. Cells were washed again and incubated in DAPI
stain (1:5,000 dilution; Sigma) for 2 min. Finally, coverslips
were mounted onto microscope slides using Fluorescent
Mounting Medium (Dako). Appropriate negative controls were
carried out by performing the same protocol without the addi-
tion of primary antibodies. Images were taken using a confocal
Zeiss 700 microscope and processed with the Zeiss software.
ASO Transfections
CECs were transfected with ASOs complexed with DarmaFECT 4
transfection reagent (Dharmacon), in accordance with the man-
ufacturer’s instructions. The following ASOs were used; Control
ASO: 50-mG*mG*mU*mG*mG*mA*mU*mC*mA*mC*mG*mA*
mG*mU*mU*mC*mA-30, (CAG)7 therapeutic oligo: 50-mC*mA*
mG*mC*mA*mG*mC*mA*mG*mC*mA*mG*mC*mA*mG*mC*
mA*mG*mC*mA*mG-30. m denotes 20-O-Methyl ribonucleo-
tide, * denotes phosphthioate linkages.ThA final oligo concentration of 200 nM was selected for all exper-
iments based on optimization data presented in Figure S1. All ASO
treatment experiments were performed 24 hr post transfection.
Fluorescence In Situ Hybridization (FISH)
CECs grown in chamber slides were washed once with PBS and
fixed with 4% PFA in PBS for 10 min at room temperature. Once
fixed, cells were washed twice with PBS and permeabilized with
70% ethanol for 15min at room temperature. Cells were rehydrated
using a 50% formamide and 23 SSC buffer for 5 min at room tem-
perature. Cells were incubated overnight at 37C in hybridization
solution containing 50% formamide, 23 SSC, 10% dextran sulfate,
0.2% BSA, 1 mg/mL yeast tRNA, and 12 mg/mL of Cy3-(CAG)7
probe. Cells were washed thoroughly using 50% formamide in
2 3 SSC followed by 50% formamide in 0.1 3 SSC before being
stained with DAPI (1:5,000 dilution; Sigma) for 2 min at room tem-
perature. Cells were washed with PBS and coverslips were mounted
onto the microscope slide using fluorescent mounting medium
(Dako). Images of foci were taken using a confocal Zeiss 700 micro-
scope and processed with the Zeiss software.
Quantitative Foci Image Analysis
Z stack images of transfected and stained CECs were processed
using Zeiss software. Images for each independent CEC line were
taken using the same image acquisition parameters. Post capture,
z stacks were processed as maximum intensity projection images.
RNA foci were quantified by segmentation using CellProfiler
(Broad Institute).28 Nuclei were defined in the 405 nm (DAPI)
channel, after a median filter was applied, by adaptive maximum
correlation thresholding, followed by form-factor and eccentricity
filtering. RNA foci were defined in the 561 nm (Cy3) channel, after
a median filter was applied, as objects within the perimeter of a
nucleus, using per-nucleus robust background thresholding,
with parameters set per cell line, due to differences in staining
intensity. Cells with high background in FISH staining, defined
as mean intensity per nucleus, were discarded to reduce segmenta-
tion error. A minimum of 100 nuclei per independent condition
and cell line were analyzed.
Dual FISH and ICC Assay
Following PFA fixation, cells were washed with PBS and then incu-
bated in blocking solution containing 10% donkey serum, 0.5%
Triton X-100, 3% BSA, and 0.4 U/mL RNase inhibitor in PBS for
1 hr at room temperature. Cells were subsequently incubated
with mouse anti-MBNL1 antibody (1:1,000 in blocking solution;
kindly provided by Thornton Lab, Chicago) overnight at 4C.
Following primary antibody incubation, cells were washed with
PBS and incubated with secondary anti-mouse antibody conju-
gated with Alexa Fluor 488 (1:1,000 in 0.5% Triton X-100, 3%
BSA) for 1 hr at room temperature. Cells were again washed with
PBS and post-fixed in 4% PFA in PBS for 10 min. FISH was subse-
quently performed, in accordance with methods stated above.
Quantitative Image Analysis of MBNL1 Puncta
A minimum of ten images per condition for each transfected and
stained CEC line were taken for analysis purposes, using a confocal
Zeiss 700 microscope. In the same way as previously described,
CellProfiler software was used to identify and quantify MBNL1
puncta, defined in the Cy2 channel. The percentage of objects
found in a nucleus after treatment with both ASOs was plotted
individually, per cell line investigated (Figure S2).e American Journal of Human Genetics 102, 1–12, April 5, 2018 3
Figure 1. Expansion of CTG18.1 Is Associated with FECD in a British and Czech Cohort
(A) Frequency histogram comparing relative distribution of CTG repeat length in Fuchs endothelial corneal dystrophy (FECD) and age-
related macular degeneration (AMD) cohorts. The longest allele detected, per individual tested, is shown. In total the FECD (blue) and
AMD (white) cohorts comprised 450 and 550 individuals, respectively.
(B) Bar chart illustrating the relative frequency of individuals with both alleles non-expanded (NE/NE), one expanded allele (E/NE), or
both alleles expanded (E/E) in both the FECD and AMD cohorts. Expanded alleles are defined asR50 CTG repeats.
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Total RNA was extracted from primary CECs using NucleoSpin
RNA XS kit according to manufacturer’s guidelines (Macherey-
Nagel). cDNA was reverse-transcribed using a Tetro cDNA synthe-
sis kit (BIOLINE) with an oligo (dT)18 primer mix in accordance
with manufacturer’s guidelines. Reverse transcription PCR was
performed using intron spanning primers listed in Table S2 using
GoTaq Green Master mix (Promega) and standard cycling param-
eters. The identities of all amplified products were confirmed by
Sanger sequencing using standard methodologies. The relative
intensities of PCR-amplified products resolved on agarose gels
were calculated using Image Lab software package (BioRad).
Intraocular Administration of ASOs
C57BL/6 mice (n ¼ 12) were given a single intravitreal administra-
tion into both eyes of Cy-3-labeled 20Ome-PS-(CAG)7 at doses of
0.025, 0.01, or 0.05mg in1mLof PBS, PBSonly, or amolar equivalent
of freeCy3 label conjugated to theASO.Micewere sacrificed at 48hr
following intravitreal injection (IVT). IVT injection method: Mice
were anesthetized using ketamine hydrochloride/medetomidine
hydrochloride i.p. Both eyes were dilated with 1% tropicamide and
2.5% phenylephrine drops. Injections of 1 mL were made below the
limbus using a 32 g needle attached to a 2.5 mL Hamilton syringe,
and animals were then recovered using antisedan.
Immunohistochemistry
Eyes were enucleated and immersion fixed in 4% PFA for 24 hr
prior to rapid freezing in OCT imbedding compound. Eyes were
removed and cryoprotected by overnight incubation (at 4C) in
30% sucrose solution. Corneal tissue sections (16 mm) were cut
on a cryostat and collected onto charged slides and viewed
immediately on a confocal fluorescence microscope.
Statistical Analyses
To test for associations between FECD disease affection status and
polymorphic markers, we built logistic regression models in the
above described groups of affected subjects and control subjects.
FECD diagnosis was the outcome and the number of alleles with
50 or more repeats was used as the independent variable. Three
association models were built: the first model was run in both
male and female participants and included adjustment for sex.
The other two models were sex specific, restricted to strata of4 The American Journal of Human Genetics 102, 1–12, April 5, 2018male and female participants only (therefore not adjusted for
sex). All the models were tested for significance using the ‘‘glm’’
function from the R 3.4.1 statistical software base packages.
Statistical analyses of CECs were performed with GraphPad
Prism 6 software. A chi-squared test was used to analyze differ-
ences in the distribution of foci incidence between the cells treated
with the control and the (CAG)7 ASO. Odds ratio tests were per-
formed to analyze whether the likelihood of finding 0, 1, 2, 3, or
4 or more foci after treatment was increased or decreased. An un-
paired two-tailed t test was used to calculate the difference inmean
number of MBNL1-positive foci per nucleus between control and
(CAG)7 ASO treatments. A one-way analysis of variance (ANOVA)
using Dunnett’s multiple comparisons test with a single pooled
variance was used to analyze differences between mean amplicon
expression in expansion-negative and expansion-positive CEC
lines compared with controls. Paired two-tailed t tests were
conducted to analyze the effect of (CAG)7 versus control ASO
treatment on amplicon expression, for each respective transcript
investigated. Data are represented as means5 1 SD for bar graphs
throughout the manuscript.Results
Expansion of the CTG18.1 Trinucleotide Repeat Confers
Significant Risk for FECD
A highly significant association between expansion of the
CTG18.1 trinucleotide repeat (conservatively defined
as R50 repeats) and FECD was identified (OR ¼ 76.47;
95% CI: 47.45–123.2; p ¼ 5.69 3 1071) in the white
European-only portion of the cohort (n ¼ 392; Table 1).
The distribution of the CTG18.1 expansion lengths among
individuals affected by FECD and age-related macular
degeneration (AMD), used as an ethnically matched con-
trol population for the purpose of this study, are summa-
rized in Figures 1A and 1B and Table 1. For the AMD
cohort, 4.2% (23/550) had one expanded copy (R50
repeats) of the CTG18.1 allele, in line with reports from
other unaffected populations screened for control pur-
poses,9,12–14 and none were found to have two expanded
alleles. In contrast, 76.4% (344/450) of the FECD cohort
Figure 2. CTG18.1-Associated RNA Foci Occur in a Tissue-Specific Manner
(A) Fluorescence in situ hybridization (FISH) was used to detect CUG-specific RNA foci in fibroblast and corneal endothelial cells (CECs)
lines derived from three individuals with FECD and expanded TCF4 alleles. Fibroblast line BJL, non-expanded (NE) FECD, and healthy
CECs were used as negative controls. Myotonic dystrophy 1 (DM1) fibroblasts were used as a positive control for foci detection
(arrowheads). Each image is presented in greyscale and foci are indicated with arrowheads. Color insets (zoom panels) are presented.
(B) Representative images of foci incidence among CECs derived from FECD-affected subjects with increasing CTG18.1 repeat lengths.
Nuclei are stained with DAPI (blue). Foci detection was performed using Cy3-(CAG)7 probe (red, arrowheads). Scale bars, 10 mm.
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which 4.0% (18/450) had bi-allelic expansions. Interest-
ingly, male subjects had a higher incidence of expanded
CTG18.1 alleles (81.6% versus 72.8% with at least one
expanded allele; Table 1) and the FECD risk associated
with repeat expansion at this locus was higher in males
(OR ¼ 95.04, 95% CI: 43.08–209.70, p ¼ 1.62 3 1029)
than in females (OR ¼ 66.78, 95% CI: 36.79–121.20,
p ¼ 2.06 3 1043), supporting the hypothesis that interac-
tion of this locus with gender could be important.29
CEC Cultures as a Model of FECD
To investigate CTG18.1 expansion-associated pathology,
the occurrence of stable sense-strand-derived CUG RNA
foci in fibroblast primary cultures was investigated in
six independent fibroblast lines (F#1–6) derived from
FECD-affected subjects with expanded CTG18.1 genotypesTh(Table S3). For each line, FISH was performed using a Cy3-
(CAG)7 probe to determine the incidence of RNA-specific
foci (Figure S3). Despite identifyingmultiple bright nuclear
foci in a fibroblast line derived from a DM1 subject
(positive control), none were detected in any of the
FECD fibroblast lines investigated (Figure 2A).
On this basis, we tested the potential of using primary
CECs, derived from tissue excised during endothelial
keratoplasty, to investigate CTG18.1 expansion-associated
pathology. The native ‘‘endothelial-like’’ properties of the
CECs were confirmed by ICC and a variety of endothelial
markers including sodium-potassium transporting adeno-
sine triphosphatase (ATP1A1), zonula occludens 1 (ZO-1),
N-cadherin, N-CAM, and CD16630–32 (Figure S4). Further-
more, the cultured CECs displayed distinctive polygonal
morphology.25,33,34 FISH was performed, using the same
Cy3-(CAG)7 probe as described above, in three distincte American Journal of Human Genetics 102, 1–12, April 5, 2018 5
Figure 3. MBNL1 and MBNL2 Are Sequestered to RNA Foci in
Corneal Endothelial Cells (CECs) Derived from FECD-Affected
Subjects with CTG18.1 Expansions
Representative images of MBNL1 (A) and MBNL2 (B) protein nu-
clear localization in cell lines derived from expansion-positive
FECD-affected subjects, expansion-negative FECD-affected subjects,
and CECs derived from healthy individuals. RNA foci are labeled
with a Cy3-(CAG)7 FISH probe and DAPI is used to stain nuclei.
Co-localization of the MBNL proteins and RNA foci is represented
in the bottom row of both panels. Scale bars, 10 mm.
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matched fibroblast lines (Figure 2A). In each instance,
bright nuclear foci were detected in the FECD
CECs, similar to those previously identified in corneal tis-
sue,15,35 whereas the corresponding fibroblasts were foci6 The American Journal of Human Genetics 102, 1–12, April 5, 2018negative, suggesting that the endothelial-specific context
is important and that the cultured primary CECs represent
an ideal ex vivo system to investigate CTG18.1 expansion-
associated corneal endothelial pathology (Figure 2A).
RNA Foci Are a Biomarker of CTG18.1-Associated
Pathology in CECs
To further explore the incidence of RNA foci, we investi-
gated a total of 36 independent CEC lines derived from
FECD-affected subjects by FISH (Table S4; Figure 2B). In
summary, no foci were detected in 9 CEC lines derived
from FECD-affected subjects with CTG18.1 genotype sta-
tus ranging from 12/12 to 18/31, in addition to a further
4 control lines. Bright nuclear foci were clearly detected
in 27 CEC lines derived from individuals with alleles
ranging from 25/31 to 12/126. Interestingly, CTG18.1
allele length of 31 repeats appears to represent a critical
threshold for foci occurrence in CECs as individuals with
genotypes of 18/31 and 25/31 were foci negative and
positive, respectively. No samples were available with an
expansion in the range between 32 and 52 repeats
(Figure 2B; Table S4). On this basis, we classified CEC lines
selected for further experimental investigation as non-
expanded (NE) if both CTG alleles contained <31 repeats,
whereas those with at least one allele R53 repeats were
considered expanded (Tables S3–S9).
RNA Splicing Factors MBNL1 and MBNL2 Are
Sequestered by Nuclear RNA Foci
To determine whether RNA binding proteins were being
sequestered by the RNA foci, in the cultured FECD CECs,
we employed a dual FISH and ICC approach. The nuclear
distribution of MBNL1 and MBNL2 was investigated in
multiple CEC lines derived from individuals with and
without expanded copies of the repeat (Table S5). MBNL1
displayed a diffuse nuclear localization in three non-
expanded (NE) CEC lines and no foci were detected, as
anticipated (Figure 3A). Striking co-localization was
observed between MBNL1 and the CUG-specific RNA foci
in all three independent CTG18.1 expansion-positive
lines examined (Figure 3A), concordant with a previous
observation made in FECD-diseased tissue.15 Similarly,
the recruitment of MBNL2 to CUG-specific nuclear RNA
foci was also detected in expansion-positive CECs (n ¼ 3)
and MBNL2 displayed diffuse nuclear localization in
expansion-negative and control CEC lines (n ¼ 4)
(Figure 3B). These data demonstrate that RNA splicing
factors are recruited to CUG RNA foci and suggest that
this recruitmentmay induce a functional deficiency of pro-
teins that would be predicted to alter alternative splicing
events, in a similar downstream pathway to what has
been established for DM1.18–22,36
Expansion of CTG18.1 Is Associated with Altered mRNA
Processing
Transcriptomic analysis of endothelial tissue derived from
individuals affected with FECD has previously suggested
Figure 4. Altered Pre-mRNA Splicing Events Are Specific to CTG18.1 Expanded Corneal Endothelial Cells (CECs) Derived from
FECD-Affected Subjects
(A) Reverse transcriptase (RT)-PCRs reactions are shown for three selected alternative splicing events investigated for the following tran-
scripts: MBNL1, MBNL2, and NUMA1. Samples are grouped in the following categories; controls (lanes 1–4), FECD CTG18.1 expansion
positive (lanes 5–8), and FECD CTG18.1 expansion negative (lanes 9–11).
(B) Schematic representations of RT-PCR-generated amplicons are provided for each transcript-specific reaction. Primer locations are
denoted with arrows. The respective sizes of all amplified products are given.
(C) Percentage expression of amplicons of interest (A or B) relative to total amplified products, per reaction, are presented as a mean
for each respective group (C, E, and NE). Error bars represent 51 standard deviation. p values were calculated by one-way analysis of
variance (ANOVA); ****p < 0.0001, ***p < 0.001, ns, non-significant.
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CTG18.1 expansion-positive tissue.15,37 Therefore, we
investigated whether signatures of differential splicing
were present in cultured primary CECs. Total RNA was iso-
lated from four FECD CTG18.1 expansion-positive and
three FECD CTG18.1 expansion-negative CEC lines
(CTG18.1 genotype listed in Table S6), in addition to
four CEC lines derived from healthy control subjects. RT-
PCR analysis was performed to investigate differential
splicing of the three most robustly detected aberrant
events observed in tissue derived from affected subjects:
MBNL1 (MIM: 606516), MBNL2 (MIM: 607327), and
NUMA1 (MIM: 164009).37 For each transcript analyzed,
significantly different (p < 0.001) patterns of splicing
were observed only in the FECD expansion-positive lines
compared to FECD expansion-negative and unaffected
control lines, supporting the hypothesis that abnormal
regulation of mRNA processing is specific to CTG18.1-
related pathology (Figure 4).
ASO Treatment Reduces the Incidence of Nuclear RNA
Foci
A fully 20-O-methyl-phosohorothioate(20-O-Me-PS) modi-
fied (CAG)7 ASO complimentary to (CUG)n repeats has pre-
viously been shown to effectively silenceDMPK1 trinucleo-
tide repeat expansion transcripts in a DM1 humanized
animal model and human DM1 cell system and to reduce
the number of DM1-associated RNA foci in a repeat-
length-dependentmanner.23,24We therefore testedwhether
transfecting with 20-O-Me-PS-(CAG)7 ASOs, complimentary
toTCF4CTG18.1-derived transcripts, could induce a similar
reduction in CUG-specific RNA foci, a biomarker of
CTG18.1-related pathology, in the CEC cultures.ThA series of six FECDCEC lines, with confirmed expanded
CTG18.1 genotypes (Table S7), were selected for ASO treat-
ment. Each independent line was transfected with 200 nM
of either (CAG)7 or a control ASO of identical chemical
structure and of comparable length but specific to a
completely unrelated sequence. A final oligo concentra-
tion of 200 nM was selected for all experiments based on
optimization data (Figure S1). All lines analyzed showed
a striking reduction in foci number in response to
(CAG)7 ASO treatment (Figures 5 and S5). Violin plots
summarize the shift in distribution of RNA foci-positive
nuclei observed comparing the control ASO-treated
CECs versus (CAG)7 ASO treatment (n ¼ 6) (chi square
test, c2 ¼ 160.78, df ¼ 4, p ¼ 0.001; Figure 5B). The per-
centage of nuclei containing zero, one, two, three, and
four or more foci was analyzed, and odds ratio (OR) test
confirmed that the likelihood of finding zero foci was
significantly increased in cells treated with the (CAG)7
ASO compared to cells treated with the control ASO
(OR ¼ 6.2024, 95% CI, p < 0.0001).
ASO Treatment Rescues MBNL1 Nuclear Localization
To determine the effect of (CAG)7 ASO treatment
on MBNL1 distribution, four independent expansion-
positive CEC lines (Table S8) were selected and ICC was
performed, following treatment with either the (CAG)7
or control ASO. In all four lines treated with the (CAG)7
ASO, there was an obvious redistribution of MBNL1
and a significant reduction in MBNL1-positive puncta
(p < 0.0001), demonstrating that ASOs can rescue aber-
rant MBNL1 nuclear localization associated with the
CTG18.1 expansion-related pathology (Figures 3A, 5D,
5E, and S2).e American Journal of Human Genetics 102, 1–12, April 5, 2018 7
Figure 5. ASO-Mediated Treatment of Corneal Endothelial Cells (CECs) Significantly Reduces Foci Number and Rescues MBNL1
Nuclear Localization
(A) Foci incidence for control and (CAG)7 antisense oligonucleotide (ASO)-treated FECD-affected subject-derived CECs. The graph shows
percentages of nuclei that contain 0, 1, 2, 3, and 4 or more foci after treatment with the different ASOs. Mean5 SD are represented in
each case (n ¼ 6).
(B) Violin plots representing the distribution of the frequencies of each group of nuclei (containing 0, 1, 2, 3, and 4 or more foci) in cells
treated with control and (CAG)7 ASOs (n ¼ 6).
(C) Representative images of ASO treatment on foci incidence. Sense RNA foci detection using Cy3-(CAG)7 probe (red). Scale bars, 10 mm.
(D) Number of MBNL1 puncta present per nucleus when cells were treated with either a control ASO or with the (CAG)7 ASO. The mean
5 SD from 4 independent expansion-positive CEC lines, where aminimumof 95 nuclei were evaluated per line. p values were calculated
using an unpaired two tailed t test; ****p < 0.0001.
(E) Representative example illustrating the reduction of MBNL1 puncta and the changes in MBNL1 localization when cells were treated
with control and (CAG)7 ASOs. In all cases CECs were treated with 200 nM (CAG)7 or control ASO for 24 hr. Scale bars, 25 mm.
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We investigated the potential of (CAG)7 ASO treatment
to reverse the shift in alternative splicing events
previously observed in expansion-positive CEC lines
(Figure 4). Ten FECD expansion-positive CEC lines
(Table S9) were treated with either the (CAG)7 or control
ASO. Following treatment, RNA was extracted and
RT-PCR was performed. For both MBNL1 and MBNL2
there was a highly significant (p < 0.0001) shift in
the relative proportions of alternatively spliced tran-
scripts after (CAG)7 ASO treatment (n ¼ 10) toward the
control CEC spliceoform distribution (Figure 6). Further-
more, a significant (p% 0.05) shift in the relative propor-
tions of alternatively spliced transcripts was also demon-
strated for NUMA1 (n ¼ 10) (Figure 6). These data
therefore demonstrate that the (CAG)7 ASO is effective
at rescuing the differential splicing events associated
with CTG18.1 expansion-related pathology (Figures 4
and 6).8 The American Journal of Human Genetics 102, 1–12, April 5, 2018Intraocular Injections Enable Effective In Vivo Delivery of
ASOs to the Corneal Endothelium
To assess the likely accessibility of ASOs to the corneal
endothelium, C57B16 mice were injected intravitreally
with varying concentrations (0.025, 0.01, and 0.005 mg)
of Cy-3-labeled 20Ome-PS-(CAG)7. Confocal fluorescence
microscopy revealed that the ASO was present in corneal
endothelium, keratocytes, and stroma, specifically
accumulating in both the nuclear and perinuclear region
of both the endothelial and stromal cells. This localization
increased in a dose-dependent manner, showing
stronger accumulation in cell layers at 48 hr post-dosing
(Figure S6). ASOs with identical chemistry, following intra-
ocular injection, have previously been shown in vivo to
display a similar peri-nuclear and nuclear localization in
other cell types in conjunction with effective molecular ac-
tivity.38 These data highlight the potential for the (CAG)7
ASO to target CECs in vivo, an essential prerequisite for
the effective delivery of an ASO-mediated FECD therapy.
Figure 6. ASO Treatment Rescues Differential Splicing Events Underlying CTG18.1-Associated Pathology
(A) Representative RT-PCR images for non-treated samples with either expanded (E) or control (C) (non-expanded CTG18.1 genotypes)
are shown on the far left, for reference purposes. Representative RT-PCRs are shown for three independent ASO-treated CEC lines.
(B) Schematic representations are provided for each respective reaction. Primer locations are denoted with arrows. The respective sizes of
all amplified products are given.
(C) Percentage expression of amplicons of interest (A or B) relative to total amplified products, per reaction, are presented as a mean for
control-ASO versus (CAG)7 ASO-treated groups. The mean from 10 independent CEC lines 5 SD. In all cases CECs were treated
with 200 nM (CAG)7 or control ASO for 24 hr. p values were calculated using a paired two tailed t test for each event investigated;
****p < 0.0001, *p < 0.05.
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ASOs have recently emerged as a powerful therapeutic op-
tion for disease intervention, including those caused by
trinucleotide repeat expansions.10,39–42 Here we show that
a non-coding CTG trinucleotide repeat expansion in
TCF4 (CTG18.1) confers greater than 76-fold risk for
FECD in a large white British andCzech cohort. We demon-
strate that primary CECs derived from FECD-affected
subjects display the predicted hallmarks of primary and
downstream repeat-expansion-associated pathology, and
subsequently show that these changes are reversed by an
ASO treatment specifically targeted at the CTG18.1 trinu-
cleotide repeat expansion. An ASO-based treatment could
therefore offer an innovative therapeutic approach that
could benefit a substantial number of individuals affected
by this common and sight-threatening condition.43
The data presented here suggest that the TCF4 repeat
expansion leads to CEC-specific dysfunction, as unlike
other trinucleotide expansion diseases, nuclear RNA foci
are not observed in case-matched fibroblasts. These data,
at least in part, explain the corneal-specific phenotype re-
sulting from repeat expansions in this widely expressed
gene and highlight the importance of investigating the
trinucleotide expansion in primary human CECs. TCF4
haploinsufficiency causes the systemic condition Pitt-
Hopkins syndrome, but the noncoding repeat expansion
exclusively affects the cornea.44,45 Interestingly, a recent
study has reported that FECD is a common ocular finding
in DM1-affected case subjects.46 Combined with our data,
this suggests that the corneal endothelium is susceptible toThtoxicity induced by these genetically distinct repeat expan-
sions, driven by RNA foci.
It is well established for a wide range of repeat expansion
disorders that disease onset and incidence of RNA foci
manifest only above a critical level of nucleotide re-
peats.47 A threshold for CTG18.1 repeat length and FECD
association is yet to be fully defined. Performing FISH
with 36 distinct CEC lines derived from FECD-affected sub-
jects has enabled us to identify the threshold for the num-
ber of repeats required to produce nuclear RNA foci in our
model (Figure 2B; Table S4). Nine CEC lines with CTG18.1
genotypes ranging from 12/12 to 18/31 were found to lack
RNA foci. A further 27 lines with CTG18.1 genotypes
ranging from 25/31 to 12/126 were all found to exhibit
punctate nuclear RNA foci. These data allow us to correlate
CTG18.1 genotype status with CUG RNA foci incidence
and indicate that a repeat size of more than 31 trinucleo-
tide repeats is sufficient to drive the accumulation of stable
CUG RNA foci in primary CECs (Figure 2B; Table S4). This
identified threshold also correlates notably with the bi-
nominal distribution of CTG18.1 repeat length observed
in our FECD cohort (Figure 1A), which is likely attributed
to the instability of the repeat above approximately 30
copies. Interestingly, RNAs containing more than 30
CUG repeats have recently been demonstrated to undergo
phase separation to form nuclear foci.47 The threshold for
this repeat length-dependent process (30 CUG repeats) is
remarkably similar to what we have observed with respect
to CTG18.1-related foci occurrence in CECs (Figure 2B).
These phase separation data further support the use of
agents that disrupt RNA-RNA base-pairing, such as ASOs,e American Journal of Human Genetics 102, 1–12, April 5, 2018 9
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toxicity.47 Taken together, these data suggest that a
CTG18.1 length R32 should, in future, be considered as
FECD risk associated. We repeated the tests for association
with FECD defining the expanded repeats asR32, instead
of the previously used more conservative threshold of
R50. The association model became more significant
(p ¼ 3.79 3 1074), although the disease risk conferred
by this locus was lower (OR ¼ 34.14; 95% CI: 23.35–
49.91). Future analysis of CECs from individuals affected
by FECD with repeat lengths in the unidentified range of
31–53 could further refine this important threshold.
We investigated the downstream consequences of RNA
foci and have identified that sequestration of RNA splicing
factors, MBNL1 and MBNL2 (Figure 3), in addition to
abnormal patterns of alternative splicing were detectable
in a repeat expansion-specific manner (Figure 4). These ob-
servations reinforce the notion that such RNA structures
induce toxic gain-of-function effects that are likely to be
disrupting overall cellular homeostasis, implicating aber-
rant RNA metabolism in the pathogenesis of CTG18.1-
associated FECD.15,37 Furthermore, these data demonstrate
that these events are specific to CTG18.1-mediated FECD
and are not a general downstream consequence of the dis-
ease, given that CECs derived from FECD-affected case sub-
jects without expanded copies of the repeat did not display
features of aberrant RNA metabolism.
Importantly, we demonstrate here that an ASO targeted
to the CTG trinucleotide TCF4 expansion can ameliorate
disease-associated markers of RNA toxicity in CECs derived
from FECD-affected subjects, specifically reducing RNA foci
formation (Figures 5A–5C), prompting MBNL1 nuclear
redistribution (Figures 5D and 5E) and partially suppressing
differential splicing events (Figure 6). We additionally
demonstrate that the ASO can access the corneal endothe-
liumwhen injected intravitreally in mice (Figure S6). Entry
of fluorescently labeled ASO to the corneal endothelial cells
is an endogenous property of naked 20Ome-PS-ASOs oligo
and no other excipients are required to induce entry into
these cells. Access to the CECs is also both dose and time
dependent, suggesting that ASOs are rapidly taken up by
cells after dosing. While it may be desirable to consider a
topical eye drop therapy for FECD using an ASO approach,
this is highly unlikely to be effective using naked ASOs
given the structure of the corneal epithelium and the size
and charge of ASOs; an adjunctive delivery technology
would likely have to be considered in this case.
Future studies usingCECs fromaffected individualswill be
helpful in defining an effective ASO concentration, which
can lead to a good clinical dose estimate when considering
introduction to the anterior ocular chamber, which has a
small fixed but rapidly exchanging volume. Detailed phar-
macokinetic studies will be required to define the optimal
dosing time interval, which is expected to bemonths, based
on the rapid cellular uptake and the tissue/cellular longevity
of similar 20Ome-PS-ASOs in studies that have examined
intraocular dosing of ASOs.48 It is important to note that in10 The American Journal of Human Genetics 102, 1–12, April 5, 2018the final stages of FECD there is significant endothelial cell
loss, and consequently ASO-specific treatment is intended
to prevent further cell loss. Themost likely group of affected
individuals to benefit from such a therapeutic intervention
will be those individualswhoare in the early stages of disease
and have not yet experienced significant endothelial cell
loss. Importantly, these at-risk individuals can be effectively
identified by a CTG18.1 genotyping test.
In summary, we demonstrate proof-of-concept data that
a targeted (CAG)7 ASO treatment reduces gain-of-function
RNA toxicity induced by TCF4 CTG18.1 expansion, in a
cellular and human genomic context. With the absence
of FECD animal models, human ex vivo models are vital,
both to provide a validation of the therapeutic approach
for FECD and to continue the translation of ASO therapies
into the clinic. ASO therapies are already in clinical trials
for a variety of repeat expansion disorders including
DM141 and Huntington disease (MIM: 143100), and addi-
tionally, intraocular ASO therapies are proposed for reti-
nitis pigmentosa (RP [MIM: 268000]), RP associated with
Usher syndrome (MIM: 608400), and Leber congenital
amaurosis (MIM: 610142).49–52 We propose that our
proof-of-concept study provides evidence to translate
this therapeutic approach to FECD given the accessibility
of the diseased tissue and the relatively delayed onset
of disease, which provides a window of opportunity to
identify at risk individuals with TCF4 repeat expansions
and prevent disease progression in pre-symptomatic
individuals.Supplemental Data
Supplemental Data include six figures and nine tables and can be
found with this article online at https://doi.org/10.1016/j.ajhg.
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Figure S1. Optimization of antisense oligo (ASO) concentration used for in vitro transfections. 
Fibroblasts isolated from myotonic dystrophy type 1 (DM1) subjects harboring 50/80 CTG repeats, 1600/2400 CTG 
repeats, and control fibroblasts noted GM03991, GM04602, and GM04603 respectively (Coriell Institute) were 
transfected with 2’Ome-PS-(CAG)7 ASO at indicated concentrations using Turbofect (ThermoFisher Scientific). 
Twenty-four hours post transfection fluorescence in situ hybridization (FISH) was performed and RNA foci were 
quantified using CellProfiler (Broad Institute). A concentration of 200 nM 2’Ome-PS-(CAG)7 ASO was selected to be 
optimal, on the basis for these data, for future ASO transfection experiments in corneal endothelial cells (CECs). Scale 
bars, 10 µm. 
 Figure S2. Quantification of nuclear MBNL1-positive puncta post antisense oligo 
(ASO) treatments. The result of 4 independent Fuchs endothelial corneal dystrophy (FECD) case-
derived CEC lines, where the numbers of MBNL1 puncta were quantified after treatment with the control 
and (CAG)7 ASOs. CTG18.1 genotypes are shown in parentheses for each line investigated.  
  
 Figure S3. Fluorescence in situ hybridization (FISH) protocol detects RNA-specific 
CUG foci. Sense RNA foci detection with Cy3-(CAG)7 probe in untreated, RNase treated and DNase 
treated FECD case-derived CECs with an expanded TCF4 CTG18.1 allele (18/84). Scale bars, 10 µm. 
  
 Figure S4. Primary corneal endothelial cell (CEC) cultures display distinctive 
corneal endothelial polygonal morphology and display markers indicative of 
endothelial cell status. Endothelial markers N-Cadherin, ZO-1, ATP1A1, N-CAM and CD166 were 
observed and the epithelial marker E-Cadherin was absent in CEC lines derived from healthy tissue. 
Scale bars, 100 µm.  
 Figure S5. Antisense oligo (ASO)-mediated treatment of 6 independent FECD case-derived 
corneal endothelial cell (CEC) lines.  The effect of the (CAG)7 ASO treatment on foci incidence in each of 
the 6 independent FECD case-derived cell lines investigated is shown. CTG18.1 genotypes are shown in 
parentheses for each line investigated.    
  
Figure S6. Visualization of Cy3-labelled 2’Ome-PS-(CAG)7 antisense oligonucleotide (ASO) in corneal tissue following 
intraocular administration. C57Bl6 mice were intravitreally injected with 0.025, 0.01 or 0.005 mg of Cy-3 labelled 2’Ome-PS-(CAG)7 ASO, free 
Cy3 dye alone (identical molar amount to the ASO), or PBS.  Animals were sacrificed 48h post injection. Eyes were enucleated and immersion fixed 
in paraformaldehyde. Slides were prepared and immediately viewed on a confocal fluorescent microscope after counterstaining for cell nuclei detection 
with DAPI (blue). The location of the corneal endothelium is denoted by dashed lines. Scale bars, 20 µm. 
  
  
 
Table S1. Summary of antibodies used in this study. 
 
Target protein Source Dilution Reference 
ZO-1 Mouse 1:500 Invitrogen 
ATP1A1 Mouse 1:50 Developmental studies Hybridoma Bank (a6F) 
N-Cadherin Rabbit 1:100 Abcam (ab12221) 
N-CAM Rabbit 1:100 Cell signaling 3606s 
CD166 Mouse 1:200 Pharmingen (BD) 559260 
E-Cadherin Rat 1:500 Abcam (ab11512) 
MBNL1 Rabbit 1:2000 Lin et al, 2006 27 
MBNL2 Mouse   1:100   Santa Cruz (sc-365104) 
 
Table S2. Primers used to detect alternative splice events by reverse transcriptase (RT)-PCR. 
 
Primer Sequence 5’-3’ Amplicon sizes (bp) Optimized annealing temperature (⁰C) 
MBNL1_F TGACACCAATGACAACACAGTC 
383/329 65 
MBNL1_ R CTGGTGGGAGAAATGCTGTA 
MBNL2_ F ACAGCACCATGATCGACACAAG 
276/222 64 
MBNL2 _R AAGGATGAAGAGCACCAGGG 
NUMA1_F TACGTGCTGATGCTGAGACC 
305/263 64 
NUMA1_R CTTGCTGGCTTGGTCAGAGT 
   
 
Table S3: Fibroblast, and case matched corneal endothelial cell (CEC), lines 
investigated by fluorescence in situ hybridization (FISH). NA, not available. NI, not 
investigated. CTG18.1 repeat lengths were confirmed to be concordant between blood 
and fibroblast-derived gDNA samples.  
Fibroblast 
line 
Case matched 
CEC line 
CTG18.1 
genotype 
 
CUG RNA foci 
detected in 
fibroblasts? 
 
 
CUG RNA foci 
detected in CECs? 
 
#F1 NA 31/69 No NI 
#F2 NA 12/53 No NI 
#F3 NA 84/108 No NI 
#F4 #43 23/68 No Yes 
#F5 #47 23/70 No Yes 
#F6 #31 12/77 No Yes 
Table S4: CTG18.1 genotype of FECD case-derived corneal endothelial cell 
(CEC) lines investigated by fluorescence in situ hybridization (FISH). Cell 
lines are ordered based on CTG18.1 genotype status in ascending order. 
Genotypes were generated using case matched whole blood-derived genomic 
DNA samples. 
CEC line CTG18.1 genotype 
 
CUG RNA foci detected? 
 
#94 12/12 No 
#139 12/12 No 
#42 12/15 No 
#86 12/15 No 
#32 12/16 No 
#46 26/27 No 
#190 15/16 No 
#211 12/23 No 
#61 18/31 No 
#181 25/31 Yes 
#50 12/53 Yes 
#136 12/58 Yes 
#8 16/62 Yes 
#38 16/62 Yes 
#152 15/68 Yes 
#43 23/68 Yes 
#33 16/70 Yes 
#47 23/70 Yes 
#120 23/70 Yes 
#70 12/74 Yes 
#49 12/76 Yes 
#192 25/76 Yes 
#31 12/77 Yes 
#193 25/79 Yes 
#25 24/80 Yes 
#29 16/81 Yes 
#37 12/82 Yes 
#92 12/84 Yes 
#88 18/84 Yes 
#115 18/84 Yes 
#34 12/87 Yes 
#137 16/88 Yes 
#63 12/97 Yes 
#67 12/98 Yes 
#121 12/100 Yes 
#44 12/126 Yes 
  
Table S6: FECD case-derived corneal endothelial cell (CEC) lines used for 
transcriptomic analysis. E, expanded, NE, non-expanded. 
Case matched CEC 
line 
CTG18.1 genotype 
 
CTG18.1 Genotype Classification 
 
#138 16/84 E 
#140 12/106 E 
#149 16/93 E 
#154 12/81 E 
#125 13/18 NE 
#141 18/24 NE 
#145 22/28 NE 
 
  
Table S5: FECD case-derived corneal endothelial cell (CEC) lines used for dual 
fluorescence in situ hybridization (FISH) and immunocytochemistry (ICC) 
experiments. NI, not investigated, E, expanded, NE, non-expanded. 
Case derived 
CEC line 
CTG18.1 
genotype 
 
CTG18.1 
Genotype 
Classification 
 
CUG RNA 
foci 
detected? 
 
 
MBNL1 
sequestered? 
 
 
MBNL2 
sequestered? 
 
#121 12/100 E Yes Yes NI 
#190 15/16 NE No No NI 
#192 25/76 E Yes Yes NI 
#193 25/79 E Yes Yes NI 
#204 12/99 E Yes NI Yes 
#206 25/76 E Yes NI Yes 
#211 12/23 NE No NI No 
#226 12/18 NE No No NI 
 Table S7: FECD case-derived corneal endothelial cell (CEC) lines used for 
antisense oligonucleotide (ASO) treatment experiments. E, expanded.  
Case matched CEC 
line 
CTG18.1 genotype 
 
CTG18.1 Genotype Classification 
 
#88 18/84 E 
#92 12/84 E 
#115 18/84 E 
#121 12/100 E 
#50 12/53 E 
#63 12/97 E 
 
 
Table S8: FECD case-derived corneal endothelial cell (CEC) lines used to 
assess MBNL1 localization, following antisense oligonucleotide (ASO) 
treatment. E, expanded. 
Case matched CEC 
line 
CTG18.1 genotype 
 
CTG18.1 Genotype Classification 
 
#202 12/96 E 
#208 24/107 E 
#212 12/93 E 
#218 15/92 E 
 
 
Table S9: FECD case-derived corneal endothelial cell (CEC) lines used for 
transcriptomic analysis, following antisense oligonucleotide (ASO) 
treatment. E, expanded. 
Case matched CEC 
line 
CTG18.1 genotype 
 
CTG18.1 Genotype Classification 
 
#162 71/113 E 
#173 16/72 E 
#179 15/61 E 
#210 14/80 E 
#215 12/73 E 
#216 18/91 E 
#219 18/88 E 
#220 15/103 E 
#223 12/63 E 
#224 12/89 E 
 
 
